Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Isolagen has completed enrollment of approximately 120 patients in its Phase II/III Study IT-A-008 investigating the Isolagen therapy for the treatment of moderate to severe acne scars.
Subscribe to our email newsletter
Treatments, which will be administered at seven clinical sites across the US have commenced.
Declan Daly, CEO of Isolagen, said: “Concerning our pivotal clinical program on wrinkle correction, we expect to review the six month efficacy data on our Phase III study of the Isolagen therapy prior to September 1, 2008. We have focused our resources to meet the goals of advancing this program and our acne program and we are attempting to raise additional funding.”